A. Gordon

A Rapid Genotyping Panel for Detection of Primary Central Nervous System Lymphoma.

Matthew J. Frigault, D. Cahill, B. Nahed, 2021, Blood.

Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas

S. Schuster, A. Mato, J. Svoboda, 2014, Cancer.

A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive Cancer

Amanda J. Thomas, D. Neuberg, J. Folkman, 2005, Journal of pediatric hematology/oncology.

Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial.

E. Wong, A. Norden, T. Batchelor, 2020, The oncologist.

A prospective, blinded analysis of A‐PROTEIN (recoverin or CAR protein) levels in pediatric patients with central nervous system tumors

L. Goumnerova, M. Kieran, N. Ullrich, 2009, Pediatric blood & cancer.

Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens

P. Brastianos, J. Dietrich, Naema Nayyar, 2023, Neurology.

Combined lenalidomide, low‐dose dexamethasone, and rituximab achieves durable responses in rituximab‐resistant indolent and mantle cell lymphomas

S. Schuster, A. Mato, J. Svoboda, 2014, Cancer.

Phase II Trial of Lenalidomide - Dexamethasone - Rituximab In Relapsed or Refractory Indolent B-Cell or Mantle Cell Lymphomas Resistant to Rituximab

S. Schuster, J. Svoboda, T. Ahmadi, 2009 .